» Articles » PMID: 12781551

Haemophilias A and B

Overview
Journal Lancet
Publisher Elsevier
Specialty General Medicine
Date 2003 Jun 5
PMID 12781551
Citations 236
Authors
Affiliations
Soon will be listed here.
Abstract

The haemophilias are inherited disorders in which one of the coagulation factors is deficient. Although deficiencies of factor VIII (haemophilia A) and factor IX (haemophilia B) are well recognised, von Willebrand's disease is much more common. Rare defects can occur in any of the coagulation factors. In the past, men with haemophilia were likely to die in their youth. With advances in diagnosis, and especially with development of safe and effective treatment, affected individuals can now look forward to a normal life expectancy. Complications of the disorder, particularly the development of antibodies that make treatment ineffective, and of treatment, such as transfusion-transmitted infections, have taken a severe toll on these patients. The future holds the realistic possibility of gene therapy. However, we must not forget that haemophilia is a worldwide disorder that requires significant economic resources not available for the majority.

Citing Articles

Extravascular coagulation regulates haemostasis independently of activated platelet surfaces in an in vivo mouse model.

Sakata A, Tatsumi K, Matsumoto N, Mackman N, Harada S, Kawasaki R Commun Biol. 2025; 8(1):390.

PMID: 40055470 PMC: 11889134. DOI: 10.1038/s42003-025-07838-x.


Gene therapy in hemophilia: the dawn of a new era.

Gualtierotti R, Giachi A, Bitto N, La Mura V, Peyvandi F Res Pract Thromb Haemost. 2025; 9(1):102640.

PMID: 39810981 PMC: 11730942. DOI: 10.1016/j.rpth.2024.102640.


Epilepsy and Other Neurological Complications in Pediatric Patients With Hemophilia Complicated With Intracranial Hemorrhage: A Retrospective Case Series.

Eguchi Y, Ishikawa N, Kobayashi Y, Mizoguchi Y, Okada S Cureus. 2024; 16(11):e74261.

PMID: 39717343 PMC: 11663621. DOI: 10.7759/cureus.74261.


Ex vivo evaluation of the effect of plasma-derived factor VIII/von Willebrand factor in patients with severe hemophilia A on emicizumab prophylaxis.

Raventos A, Arias-Salgado E, Perez A, Alvarez-Roman M, Butta N, Monzon Manzano E Clin Exp Med. 2024; 25(1):14.

PMID: 39708197 PMC: 11663164. DOI: 10.1007/s10238-024-01528-4.


Advances in Development of Drug Treatment for Hemophilia with Inhibitors.

Wichaiyo S ACS Pharmacol Transl Sci. 2024; 7(12):3795-3803.

PMID: 39698264 PMC: 11650736. DOI: 10.1021/acsptsci.4c00560.